In 2017, Fonseca et al. reported that “both CB1 and CB2 are seven-transmembrane domain receptors coupled to Gi/o protein and their activation triggers several cancer pathways, including antiproliferative and pro-apoptotic effects attributed to activation of the alpha subunit of Gi/o that leads to inhibition of adenylate cyclase, which attenuate cyclic adenosine monophosphate (cAMP) synthesis and protein kinase A (PKA) activity, with the downregulation of gene transcription [10]. The gene discussed is CNR2; the disease is cancer.